Denosumab Prolia For Postmenopausal Osteoporosis. Oct 18, 2010 · denosumab (prolia) for postmenopausal osteoporosis. Feb 15, 2012 · denosumab (prolia) is a subcutaneously administered human monoclonal antibody that decreases bone resorption by inhibiting the formation and activity of osteoclasts.
Funding and disclosures supported by amgen.
Dec 01, 2010 · denosumab is the first monoclonal antibody for the treatment of postmenopausal osteoporosis. When to take denosumab instead of alendronate for osteoporosis? It has been licensed in the eu for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and also for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Recombinant antibodies, scfv fragment antibodies
Post a Comment for "Denosumab Prolia For Postmenopausal Osteoporosis"